This site is intended for health professionals only

Combination therapy increases progression-free survival in advanced prostate cancer

In advanced prostate cancer, combining ipatasertib with abiraterone improved progression-free survival compared to abiraterone alone.

Interim results from a Phase III trial have demonstrated that in men with advanced prostate cancer, combing the anti-androgen, abiraterone with ipatasertib, extends the time before disease progression. In men with prostate cancer, inactivation of the PTEN tumour suppressor gene can be found in up to 50% of castration-resistant tumours. Loss of PTEN function leads to activation of the AKT pathway and is strongly associated with adverse patient outcomes. Ipatasertib is a potent and novel, inhibitor of ATK, which is is one of the most frequently activated protein kinases in human cancers and which plays a critical role in tumour growth, proliferation, survival as well as resistance to anticancer therapy. Thus adding ipatasertib to a treatment regime with abiraterone, simultaneously targets two of the aberrant pathways in prostate cancer. This is particularly important given that metastatic castrate-resistant prostate cancer has a poor prognosis.

Findings

In total, 554 (50%) men were assigned to the placebo–abiraterone group and 547 (50%) to the ipatasertib–abiraterone group and the median follow-up duration was 19 months. Among 261 men in the placebo–abiraterone group and 260 in the ipatasertib–abiraterone group), median radiographical progression-free survival was 16·5 months (95% CI 13·9–17·0) in the placebo group and 18·5 months (16·3–22·1) in the ipatasertib–abiraterone group. This equates to a 23% reduction in the risk of disease progression (hazard ratio, HR = 0.77, 95% CI 0.61 – 0.98, p = 0.04).

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Although this is an ongoing trial, the authors of this interim analysis concluded that the combined AKT and androgen-receptor signalling pathway inhibition with ipatasertib and abiraterone is a potential treatment for men with PTEN-loss metastatic castrate-resistant prostate cancer, a population with a poor prognosis.

Citation

Sweeney C et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet 2021






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x